Last 52.80
Change Today -1.10 / -2.04%
Volume 464.9K
INTP On Other Exchanges
Symbol
Exchange
OTC US
Tel Aviv
As of 9:24 AM 12/21/14 All times are local (Market data is delayed by at least 15 minutes).

intec pharma ltd (INTP) Snapshot

Open
$54.40
Previous Close
$53.90
Day High
$55.00
Day Low
$52.30
52 Week High
02/27/14 - $106.90
52 Week Low
12/21/14 - $52.30
Market Cap
142.6M
Average Volume 10 Days
487.3K
EPS TTM
$-0.08
Shares Outstanding
270.0M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for INTEC PHARMA LTD (INTP)

Related News

No related news articles were found.

intec pharma ltd (INTP) Related Businessweek News

No Related Businessweek News Found

intec pharma ltd (INTP) Details

Intec Pharma Ltd., a drug development company, develops improved formulations of drugs using gastric retention technology. Its product portfolio includes Accordion Pill Carbidopa/Levodopa, a Phase II gastric-retentive dosage form for the treatment of Parkinson’s disease; and Accordion Pill – Zaleplon, a Phase II drug for treatment of insomnia. The company is based in Jerusalem, Israel.

intec pharma ltd (INTP) Top Compensated Officers

Chief Executive Officer and Director
Total Annual Compensation: --
Co-Founder and Chairman
Total Annual Compensation: 513.1K
Chief Financial Officer
Total Annual Compensation: 432.1K
Vice President of R&D & Operations
Total Annual Compensation: 474.6K
Compensation as of Fiscal Year 2013.

intec pharma ltd (INTP) Key Developments

US Food and Drug Administration Gives Phase III Nod for Intec Pharma Ltd.'s Parkinson Treatment

Intec Pharma Ltd. announced that it had received US Food and Drug Administration (FDA) approval for carrying out a Phase III trial of its Accordion Pill Levodopa for the treatment of Parkinson's Disease. The Accordion Pill is a gastro-retentive drug delivery system.

Intec Pharma Ltd. Presents at BIO-Europe 2014, Nov-05-2014 12:45 PM

Intec Pharma Ltd. Presents at BIO-Europe 2014, Nov-05-2014 12:45 PM. Venue: Portalhaus Messe Frankfurt, Strasse der Nationen, 60327 Frankfurt, Germany.

Intec Pharma Reports Safety Phase 3 Trial Success

Intec Pharma Ltd. reported success in the safety trial for the Accordion Levodopa Pill that the company is developing. The company's share price rose 9% following the announcement. The Accordion Pill is a gastro-retentive delivery system designed to improve the performance of narrow absorption window drugs and poorly soluble drugs. Levodopa is a treatment for Parkinson's disease. The trial ended in late March, but processing of the results took several weeks. The results show that the trial endpoints were fully achieved, and that further significant consolidation of the safety profile of the Accordion Pill was obtained. The trial, which was carried out on animals, lasted a year, and was conducted in accordance with US Food and Drug Administration (FDA) requirements.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
INTP:IT 52.80 -1.10

INTP Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Depomed Inc $16.24 USD +0.52
View Industry Companies
 

Industry Analysis

INTP

Industry Average

Valuation INTP Industry Range
Price/Earnings -- Not Meaningful
Price/Sales -- Not Meaningful
Price/Book -- Not Meaningful
Price/Cash Flow -- Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact INTEC PHARMA LTD, please visit www.intecpharma.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.